News and analysis on diagnostic technologies and applications.
The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.
The Toronto-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.
The Swedish firm Biovica said this and additional studies will form the basis of a US Food and Drug Administration submission for its test measuring thymidine kinase-1.
The company attributed the revenue decline in part to working capital restraints and long manufacturing lead times, which are being addressed currently.
OvaCis is a CE-IVD marked in vitro diagnostic that can be used to assess epithelial ovarian cysts.
